Smart wristband zaps tremors away in Parkinson's and essential tremor
NCT ID NCT05842434
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This pilot study tested a wrist-worn device called Felix that delivers gentle electrical stimulation to suppress hand tremors. The device uses artificial intelligence to adjust stimulation in real time based on each person's tremor. 38 adults with essential tremor or Parkinson's disease wore the device daily to see if it safely reduces shaking. The study measured tremor severity using standard rating scales.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Felix NeuroAI Wristband (noninvasive neurostimulation device)
- What this could lead to
- If it works, this could offer a noninvasive, daily-use option to reduce hand tremors without medication or surgery.
- What could go wrong
- This is a small, early pilot study with no control group, so results may not be conclusive. The device may not work for everyone or could cause skin irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
38 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Nov 2023
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. At least 18 years of age. 2. Willing to provide written, informed consent to participate in the study. 3. For subjects with essential tremor (ET): 1. A clinical diagnosis of ET. 2. For either upper limb, a tremor severity score of 2 or higher as measured by one of the TETRAS items and a total score of 6 or higher across all TETRAS tasks. 4. For subjects with Parkinson's disease (PD): 1. A clinical diagnosis of PD (MDS-PD criteria). 2. A tremor score of 2 or higher on MDS-UPDRS question 3.15 (postural tremor) or 3.16 (kinetic tremor), OR 3. A rest tremor score of 2 or higher on MDS-UPDRS question 3.17 (rest tremor amplitude) in one upper extremity and a score of 2 or higher on MDS-UPDRS question 3.18 (constancy of tremor). 5. Stable dosage of any medication, if applicable, for 30 days prior to study entry. 6. Familiar with operating a touch-screen smartphone and connecting to Wi-Fi internet at home. 7. If necessary, have a dedicated caregiver to help with study required activities, such as putting on the study device, etc. 8. Willing to comply with study protocol requirements including: 1. Remaining on a stable dosage of current medications, if applicable, during the course of the study. 2. Remaining on stable caffeine consumption, if applicable, during the course of t the study. 3. No alcohol consumption on the day before a study visit. Exclusion Criteria: 1. Prior limb amputation or any known symptomatic peripheral neuropathy condition of the involved upper extremity. 2. Any current drug or alcohol abuse. 3. Current unstable epileptic conditions with a seizure within 6 months of study entry. 4. Pregnant or nursing subjects and those who plan pregnancy during the course of the study. 5. Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at the stimulation site. 6. Known allergy to adhesives. 7. History of Alzheimer's disease or dementia (Montreal Cognitive Assessment (MoCA)≤19). 8. Botulinum Toxin injection for hand tremor within 4 months prior to study enrollment. 9. Subject is currently participating or has participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor. 10. Subject is unable to communicate with the investigator and staff. 11. Any health condition that in the investigator's opinion should preclude participation in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Essential tremor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, 33486, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Reading the Brain's signals to predict who benefits from deep brain stimulation
- Giving Parkinson's patients a say may boost their Brain's ability to learn movement
- Brain scans probe why some Parkinson's patients freeze Mid-Step
- Can tango rewire the brain? dance program tested for Parkinson's and dementia
- Can a workout after walking practice help Parkinson's patients learn better?